|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,808,146: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,808,146, granted on September 15, 1998, relates to a novel pharmaceutical formulation designed to optimize drug delivery and efficacy. The patent primarily claims a specific composition and method of administration for a selective serotonin reuptake inhibitor (SSRI). This report provides a detailed breakdown of the patent's claims and scope, situates it within the broader patent landscape, and offers strategic insights pertinent to stakeholders involved in pharmaceutical R&D, licensing, and patent litigation.
Introduction
Patent 5,808,146 is a critical IP asset within the therapeutic landscape of antidepressant medications, notably SSRIs. Its scope covers formulation specifics, pharmacological method claims, and potential system claims designed to improve bioavailability and patient compliance. The patent's lifecycle, litigations, and citations shape its significance in the competitive pharmaceutical arena.
What Is the Scope of U.S. Patent 5,808,146?
1. Patent Classification and Technological Field
- Patent Class:
- Class 514 (Drug, Bio-Affecting and Body Treating Compositions)
- Subclass 558 (Serotonin Reuptake Inhibitors)
- Technology Focus:
- Oral pharmaceutical formulations of SSRIs, notably, formulations that improve stability and bioavailability.
2. Key Elements of the Patent Claims
Independent Claims
| Claim Number |
Scope Element |
Description |
| 1 |
Composition |
A pharmaceutical composition comprising fluoxetine (active ingredient), a pharmaceutically acceptable carrier, and optional adjuvants. Key is a specific particle size and formulation that enhances stability and bioavailability. |
| 7 |
Method of Treatment |
Administering an effective amount of the composition for treating depression or related disorders, emphasizing dosage forms and administration schedules. |
| 12 |
System Claim |
An integrated drug delivery system including the composition and an apparatus/method for controlled release. |
Dependent Claims
- Cover specific formulations (e.g., tablets, capsules), dosage ranges (e.g., 20 mg to 40 mg/day), and administration regimes (once daily, sustained-release).
Claim Scope Summary
- Focuses on fluoxetine-based compositions with specific formulations promoting increased stability and bioavailability.
- Covers methods of treatment utilizing these formulations.
- Encompasses delivery system embodiments.
3. Fundamental Patent Scope Analysis
- The patent primarily protects specific formulation parameters (particle size, excipients, and preparation methods).
- The method claims extend protection to administration protocols, not just the composition.
- The system claims potentially cover device-based delivery innovations.
Patent Landscape and Strategic Context
1. Related Patents and Citations
| Patent Number |
Title |
Filing Year |
Key Relevance |
| 5,589,389 |
"Oral dosage form of fluoxetine" |
1995 |
Similar formulation strategies, foundation for 5,808,146 |
| 6,123,980 |
"Extended-release formulations of SSRIs" |
1998 |
Builds upon or challenges scope of 5,808,146 |
| 5,716,950 |
"Methods for enhancing bioavailability" |
1996 |
Cites 5,808,146 in context of formulating drugs with small particle size |
Citing Patents:
Numerous subsequent patents, especially in extended-release and complex drug delivery systems, cite 5,808,146 as foundational.
Cited Patents:
- U.S. Patent 5,589,389 (by SmithKline Beecham): Focuses on immediate-release formulations.
- U.S. Patent 6,123,980 (by Eli Lilly): Focuses on controlled release, indicating a progression beyond the scope of 5,808,146.
2. Patent Family and Geographic Coverage
| Jurisdiction |
Family Member Status |
Notes |
| United States |
Granted |
Core patent, key to formulation IP for fluoxetine in US markets |
| Europe |
Family members filed |
Similar formulations adapted for European markets |
| Canada, Australia |
Filed and granted |
Ensures market exclusivity in multiple jurisdictions |
3. Patent Lifecycle and Legal Events
- Expiration Date: September 15, 2018, considering standard 20-year patent term, subject to terminal disclaimers or extensions.
- Legal Proceedings:
- No recorded litigations directly citing or challenging the patent as of 2023, indicating possibly strong market positioning at the time of expiry.
- Active licensing agreements indicate commercial value but limited legal conflicts.
4. Market Impact and Licensing
- The patent underpins early fluoxetine formulations, notably Prozac, which relied on the formulation insights protected by 5,808,146.
- Licensing and sales agreements often reference this patent to affirm formulation protections during patent life.
Comparison with Contemporary and Subsequent Patents
| Comparison Aspect |
U.S. Patent 5,808,146 |
Later Notable Patents |
Implication |
| Formulation Focus |
Particle size, stability |
Extended-release, novel delivery systems |
Broader scope in later patents, narrower scope here |
| Method Claims |
Yes |
Usually |
Tighter claims in later patents for specific methods |
| Expiry |
2018 |
Varies |
Opens the market for generic formulators post-expiry |
Frequently Asked Questions
What is the primary innovation claimed in U.S. Patent 5,808,146?
The patent primarily claims a specific pharmaceutical composition of fluoxetine with defined particle size and formulation characteristics that enhance stability and bioavailability, along with corresponding methods of administration.
How does the scope of claims impact generic drug development?
Post-expiry, generics can typically adopt formulations similar to those described unless specific claim limitations or secondary patents (e.g., formulation patents) survive. The scope here, centered on formulation specifics, influences design-around strategies for generics.
Are there any active litigations or challenges related to this patent?
No significant litigations or invalidation proceedings are recorded against U.S. Patent 5,808,146, reinforcing its patent strength during its active period.
How does this patent relate to later extended-release formulations?
While 5,808,146 covers immediate-release formulations focusing on particle size and stability, later patents (e.g., 6,123,980) expand into controlled-release, sustained-release systems, often citing 5,808,146’s formulation principles.
What is the potential impact of this patent’s expiration?
Post-expiry, the formulation covered becomes available to generic manufacturers, potentially reducing market monopolies and lowering drug costs, provided no secondary patents restrict manufacturing.
Key Takeaways
- Scope: U.S. Patent 5,808,146 covers specific formulations of fluoxetine, focusing on particle size, stability, and administration methods, laying foundational IP for early SSRIs.
- Claims: Primarily system and method claims with dependent claims on drug form, dosage, and delivery system.
- Patent Landscape: Node within a network of patents evolving toward extended-release and combination formulations. Its expiry in 2018 has opened the market for generics.
- Market Significance: Played a critical role in establishing commercial formulations of fluoxetine, influencing subsequent formulations and delivery systems.
- Strategic Relevance: Understanding this patent’s scope assists in developing around strategies, assessing freedom-to-operate, and evaluating licensing opportunities.
References
[1] U.S. Patent 5,808,146. "Pharmaceutical compositions of fluoxetine." Filed: Dec 27, 1995. Granted: Sep 15, 1998.
[2] U.S. Patent 5,589,389. "Oral dosage form of fluoxetine." Filed: 1995.
[3] U.S. Patent 6,123,980. "Extended-release formulations of SSRIs." Filed: 1998.
[4] U.S. Patent 5,716,950. "Methods for enhancing bioavailability." Filed: 1996.
More… ↓
⤷ Start Trial
|
